Latest Breaking News On - Jeffreys heier - Page 2 : comparemela.com

RGX-314 Gene Therapy for nAMD Well-Tolerated in Phase 1/2a Study

A single administration of ABBV-RGX-314 was generally well tolerated, with little to no supplemental anti-VEGF injections required in most patients at two years.

United statesJeffreys heierEuropean medicines agencyRegenxbio incDrug administrationOphthalmic consultantsVascular endothelial growth factor agentsRetinal diseaseFrom bench

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates

Ocular Therapeutix™ Announces Board of Directors and Leadership Updates
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

Drexel universityUnited statesColumbia universityNew yorkCity ofUnited kingdomCzech republicBoston universityBorough of bedfordSanjay nayakPravinu dugelPeter jarrettAllergan abbvieJoyce allaireAntony mattessichPeterk kaiser

Ocular Therapeutix (OCUL) Announces Board and Leadership Updates

Ocular Therapeutix (OCUL) Announces Board and Leadership Updates
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Peter jarrettSanjay nayakPravinu dugelAntony mattessichRabia gurses ozdenPeterk kaiserJeffreys heierOcular therapeutix incRetina dream teamOcular teamCompany as lead independent directorRetina of the companyTeam drOcular therapeutixExecutive chairmanChief scientific officer

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary Endpoint
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesMonique allaireJeffreys heierSheryl seapyAnnexon incDrug administrationSecurities exchangeRetina serviceStrategic communicationsRetina researchEuropean medicines agencyGlobal ga registrational program overviewAmerican society of retina specialistsAnnexon outlines global registrational programOutlines global registrational programGeographic atrophy

Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA

Alignment with FDA on Best Corrected Visual Acuity ≥ 15-Letter Loss as Primary Outcome Measure - Representing the Highest Value Outcome to Patients and Physicians

United statesJeffreys heierMonique allaireSheryl seapyDrug administrationSecurities exchangeRetina researchAnnexon incRetina serviceAmerican society of retina specialistsEuropean medicines agencyGlobal ga registrational program overviewStrategic communicationsBest corrected visual acuityLetter lossPrimary outcome measure